Showing 2781 results
-
Press release /In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative…
-
Press release /Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar…
-
Story /An essay by Vas Narasimhan, CEO of Novartis about the historical context and coming innovations in medicine with an introduction by Goran Mijuk.
-
Statement /
-
Webform /Novartis is committed to improving the accessibility and usability of our websites, ensuring that content and services are available to all visitors, regardless of their ability or the technology…
-
Story /Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?
-
Pulse Update /